Loading…
← CockpitCompetitor Analysis › 300363.SZ Porton Pharma Solutions Ltd. Class AOpen in the cockpit ↗

Porton Pharma Solutions Ltd. Class A300363.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

Sichuan CDMO providing custom synthesis, process development and manufacturing of drug intermediates and APIs for global pharma.

≈ A smaller Chinese Lonza/CatalentMomentum leader 95
Mkt cap
$1.66B
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$57.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-6.7 pp
WACC 10.3%
Hurdle
-8 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥21.36
1D-1.7%
1W-7.8%
1M-3.4%
3M-4.5%
6M+37.4%
YTD-8.1%
1Y-16.3%
ATR %6.2%
52w lowhigh29.7% off high

What Porton Pharma Solutions does

Sichuan CDMO providing custom synthesis, process development and manufacturing of drug intermediates and APIs for global pharma.

Paid fees for development work and then per-batch or per-kilogram supply once a customer's drug reaches commercial sale, so the pay-off from early development work comes later if the drug succeeds. Revenue therefore depends on customers' pipelines and approvals.

In one line: A smaller Chinese Lonza/Catalent.

Products and services

  • Custom API/intermediate manufacturing
  • Process development services
  • Highly potent API manufacturing

Customers

  • Global pharma and biotech companies

Where it sits in the supply chain

  • Pharma services
  • Contract development and manufacturing
  • Small-molecule CDMO

What could go right

  • Global outsourced drug-manufacturing demand

What could go wrong

  • Customer concentration
  • Biotech funding cycle sensitivity

Moat: narrow (process know-how, switching costs). Manufacturing processes are qualified into customers' regulatory filings, making supplier switches costly.

Headquarters: Chengdu, Sichuan, China · Employees: 4,359

Named competitors

Porton Pharma Solutions at a glance

Size Porton Pharma Solutions (300363.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.66B, the 1385th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.36 on 18 Nov 2026.

Performance Over six months the shares gained 37.4%, against -5.9% for the median peer and -20.0% for the China market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 6.1% over the last twelve months (peer median +8.5%); the operating margin is -2.1% (peer median 15.0%).

Valuation It trades at 3.1× enterprise value to sales against a peer median of 3.0× (10th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.7 points below its cost of capital (10.3% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026300363.SZ 144Peer median 93
Six months, rebased to 100: Porton Pharma Solutions against the median of its 20 peers (local-currency closes).

Porton Pharma Solutions financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.64BCN¥3.40BCN¥3.00BCN¥3.64BCN¥6.99B
Revenue growth—+13%-17%-48%—
Gross profitCN¥1.49BCN¥900MCN¥631MCN¥1.34BCN¥3.52B
EBITDAn/aCN¥591MCN¥173MCN¥663MCN¥2.48B
Net income-CN¥95.7MCN¥96.3M-CN¥288MCN¥267MCN¥2.01B
Free cash flowCN¥3.71BCN¥476M-CN¥85.1M-CN¥493MCN¥1.39B
Capital expenditureCN¥115MCN¥293MCN¥491MCN¥1.13BCN¥1.17B
Total debtCN¥1.57BCN¥1.84BCN¥2.33BCN¥2.21BCN¥2.11B

Quarterly statements and history in the cockpit →

Porton Pharma Solutions competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-10%0%+10%+20%002287600216600056SUDEEPPHRMJWELGRANULES11126472BIOG-BPHM600062CRON3001460022750719APN300363.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Porton Pharma Solutions is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2.5×5×7.5×002287600216600056SUDEEPPHRMJWELGRANULES11126472BIOG-B600750PHM600062CRON2142300146002275APN002219000623300363.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Porton Pharma Solutions is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%002287600216600056JWELGRANULES6472BIOG-B600750PHM600062CRON2142300146APN300363.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Porton Pharma Solutions is the large dot.

Porton Pharma Solutions competitors and peer comparison

Head to head with its named competitors (300363.SZ vs 2359.HK vs 002821.SZ vs 688073.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Porton Pharma Solutions 300363.SZ$1.66B+37%+6%-2%3.1×2.1%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%7.0×8.4%
Asymchem Laboratories (Tianjin) 002821.SZ$7.27B+20%+18%17%5.7×n/a
Bide Pharmatech 688073.SS$801M+10%+10%19%3.1×13.9%

How Porton Pharma Solutions compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Porton Pharma Solutions against its 20 peers (data as of 18 Nov 2026)
Measure300363.SZPeer medianRank in peer set
1-month return-3.4%-1.3%10th lowest of 21
6-month return+37.4%-5.9%3rd highest of 21
Distance from 52-week high-29.7%-23.4%10th lowest of 21
Revenue growth (TTM)+6.1%+8.5%10th lowest of 21
Operating margin-2.1%15.0%2nd lowest of 21
EV / Sales3.1×3.0×10th most expensive of 21
Growth the price implies (Req g, 7 yrs)2.1%2.5%10th least demanding of 19
Growth delivered (Del g)+10.4%+8.7%9th highest of 19
Hurdle (Req g minus delivered)-8.3 pp-10.5 pp9th most demanding of 19
ROIC minus cost of capital-6.7 pp+2.7 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%3.1×2.1%+10.4%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%4.0×-1.9%+10.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%0.9×-7.8%+3.9%
China Meheco 600056.SSChina$1.90B-16%+2%3%0.6×-1.3%-2.1%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%19.3×n/an/a
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%2.7×13.5%+15.3%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%3.3×23.6%+10.6%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%1.3×-1.7%+4.4%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%3.0×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%7.4×1.5%+15.5%
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%4.0×-1.9%+11.6%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%4.2×10.6%-3.9%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%1.5×-9.1%+5.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%2.4×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%4.8×13.1%+62.3%
By-health 300146.SZChina$2.56B-1%+10%11%2.0×4.8%+0.6%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%2.9×-8.7%+5.5%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%1.0×-2.1%+7.1%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%4.6×24.6%+38.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%2.9×n/an/a
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%8.4×5.0%+1.0%

Questions

Who are Porton Pharma Solutions's main competitors?
Named competitors: WuXi STA (WuXi AppTec) (2359.HK), Asymchem Laboratories (002821.SZ), Bide Pharmatech (688073.SS). The cockpit's measured peer set (industry) also includes Tibet Cheezheng Tibetan Medicine (002287.SZ), Zhejiang Medicine (600216.SS), China Meheco (600056.SS), Sudeep Pharma (SUDEEPPHRM.NS), Jamieson Wellness (JWEL.TO), Granules India (GRANULES.NS).
Is Porton Pharma Solutions expensive compared with its peers?
On ev / sales it trades at 3.1× against a peer median of 3.0×, 10th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Porton Pharma Solutions stock performed?
Over six months to 18 Nov 2026 the shares returned +37.4% against -5.9% for the median peer; over one year -16.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.